Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermtech Inc (NQ: DMTK )

3.230 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42
Open 3.230
Bid (Size) 3.150 (1)
Ask (Size) 3.330 (9)
Prev. Close 3.230
Today's Range 3.230 - 3.230
52wk Range 1.550 - 16.33
Shares Outstanding 29,940,637
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From DermTech, Inc.
Via Business Wire
DermTech's Return On Capital Employed Overview
 
Via Benzinga

Performance

YTD
+77.47%
+77.47%
1 Month
-19.05%
-19.05%
3 Month
+77.47%
+77.47%
6 Month
-27.42%
-27.42%
1 Year
-76.86%
-76.86%

More News

Read More
DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Via Benzinga
DermTech Earnings Perspective: Return On Capital Employed
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
DermTech to Present at March Investor Conferences
From DermTech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run
Via The Motley Fool
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Rises Over 1%; Oak Street Health Shares Spike Higher
Via Benzinga
US Stocks Open Higher; Nasdaq Rises 50 Points
Via Benzinga
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.